- Protein Name
- Calcium/calmodulin-dependent protein kinase type 1
- Gene Name
- CAMK1
- Organism
-
Homo sapiens
- Function
- Calcium/calmodulin-dependent protein kinase that operates in the calcium-triggered CaMKK-CaMK1 signaling cascade and, upon calcium influx, regulates transcription activators activity, cell cycle, hormone production, cell differentiation, actin filament organization and neurite outgrowth. Recognizes the substrate consensus sequence [MVLIF]-x-R-x(2)-[ST]-x(3)-[MVLIF]. Regulates axonal extension and growth cone motility in hippocampal and cerebellar nerve cells. Upon NMDA receptor-mediated Ca(2+) elevation, promotes dendritic growth in hippocampal neurons and is essential in synapses for full long-term potentiation (LTP) and ERK2-dependent translational activation. Downstream of NMDA receptors, promotes the formation of spines and synapses in hippocampal neurons by phosphorylating ARHGEF7/BETAPIX on 'Ser-694', which results in the enhancement of ARHGEF7 activity and activation of RAC1. Promotes neuronal differentiation and neurite outgrowth by activation and phosphorylation of MARK2 on 'Ser-91', 'Ser-92', 'Ser-93' and 'Ser-294'. Promotes nuclear export of HDAC5 and binding to 14-3-3 by phosphorylation of 'Ser-259' and 'Ser-498' in the regulation of muscle cell differentiation. Regulates NUMB-mediated endocytosis by phosphorylation of NUMB on 'Ser-276' and 'Ser-295'. Involved in the regulation of basal and estrogen-stimulated migration of medulloblastoma cells through ARHGEF7/BETAPIX phosphorylation (By similarity). Is required for proper activation of cyclin-D1/CDK4 complex during G1 progression in diploid fibroblasts. Plays a role in K(+) and ANG2-mediated regulation of the aldosterone synthase (CYP11B2) to produce aldosterone in the adrenal cortex. Phosphorylates EIF4G3/eIF4GII. In vitro phosphorylates CREB1, ATF1, CFTR, MYL9 and SYN1/synapsin I.
| Site |
Maximum Consensus Site Population |
Minimum Consensus Site Population |
Median Consensus Site Population |
| MPP |
8 |
4 |
6.5 |
| PIF |
11 |
11 |
11.0 |
| DRS |
22 |
2 |
10.0 |
| EDI |
20 |
3 |
18.0 |
| MT3 |
23 |
2 |
16.0 |
| AAS |
15 |
3 |
8.0 |
| CMP |
16 |
3 |
11.5 |
| PDIG |
14 |
1 |
9.0 |
| ATP |
16 |
4 |
10.5 |
| PDB ID |
Maximum Consensus Site Population |
| MPP site |
DFG site |
PIF site |
DRS site |
DEF site |
EDI site |
MT3 site |
AAS site |
LBP site |
CMP site |
PDIG site |
ATP site |
PMP site |
| Total Druggable Structures per Site |
0 |
0 |
0 |
1 |
0 |
2 |
3 |
0 |
0 |
1 |
0 |
2 |
0 |
|
4FG8
|
7 |
0 |
0 |
11 |
0 |
18 |
23 |
15 |
0 |
11 |
13 |
16 |
0 |
|
4FG9
|
8 |
0 |
0 |
22 |
0 |
20 |
18 |
0 |
0 |
12 |
1 |
16 |
0 |
|
4FG7
|
6 |
0 |
11 |
10 |
0 |
3 |
2 |
3 |
0 |
13 |
14 |
4 |
0 |
|
4FGB
|
8 |
0 |
0 |
2 |
0 |
0 |
21 |
0 |
0 |
16 |
3 |
7 |
0 |